# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

> **NCT04242199** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 182 (actual)

## Conditions studied

- Advanced Solid Tumor
- MSI-H/dMMR Tumors
- Cutaneous Squamous Cell Carcinoma
- Urothelial Carcinoma
- Cervical Cancer
- HepatoCellular Carcinoma
- Esophageal Squamous Cell Carcinoma
- Merkel Cell Carcinoma
- Small-cell Lung Cancer
- Mesothelioma
- PD-L1 Amplified Tumor (9p24.1)
- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** INCB099280

## Key facts

- **NCT ID:** NCT04242199
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-04
- **Primary completion:** 2024-08-29
- **Final completion:** 2024-11-21
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04242199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04242199, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04242199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*